Skip to main content

What the FDA labels say about taking them together

Isocarboxazid and opicapone

Opicapone's FDA label of October 15, 2025 names isocarboxazid in its drug interactions section; the isocarboxazid label PlainMeds reads does not name opicapone. The opicapone label: “DRUG INTERACTIONS 7.1 Non-Selective Monoamine Oxidase (MAO) Inhibitors Both ONGENTYS and non-selective MAO inhibitors inhibit catecholamine metabolism, leading to increased levels of catecholamines.”

Check it at the source: the isocarboxazid FDA label on DailyMed (effective April 21, 2026, Lifsa Drugs LLC); the opicapone FDA label on DailyMed (effective October 15, 2025, Amneal Pharmaceuticals LLC).

What does the isocarboxazid label say about opicapone?

Isocarboxazid's label (effective April 21, 2026) does not name opicapone in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (MARPLAN), Lifsa Drugs LLC, effective April 21, 2026 (SPL set 95fde749-44ad-4668-86c4-0ff17bca0074), via openFDA; the full label on DailyMed

What does the opicapone label say about isocarboxazid?

Opicapone label, drug interactions

DRUG INTERACTIONS 7.1 Non-Selective Monoamine Oxidase (MAO) Inhibitors Both ONGENTYS and non-selective MAO inhibitors (e.g., phenelzine, isocarboxazid, and tranylcypromine) inhibit catecholamine metabolism, leading to increased levels of catecholamines.

Source: FDA drug label (ONGENTYS), Amneal Pharmaceuticals LLC, effective October 15, 2025 (SPL set a511a531-112e-43f8-a43f-5334b0efe979), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Isocarboxazid generic labelers
0Opicapone generic labelers
IsocarboxazidOpicapone
Labeled forDepressionParkinson's disease
Boxed warningYesNo
Pharmacy cost (NADAC)n/a$24.67 per capsule 25 mg capsule
Shortage nowIn shortageNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?